Boston Scientific Epic Stent Demonstrates Positive Clinical Outcomes in ORION Trial

 

January 18, 2012

January 18, 2012 — Boston Scientific reported nine-month clinical endpoint data from its ORION trial, demonstrating positive outcomes for the Epic self-expanding nitinol stent in patients with iliac artery disease. 

"Peripheral stenting has become a recognized standard in the treatment of iliac arterial disease to restore blood flow in blocked leg arteries," said Daniel Clair, M.D., FACS, principal investigator of the trial and chairman of the Department of Vascular Surgery, The Cleveland Clinic Foundation, at the International Symposium on Endovascular Therapy (ISET) in Miami, Fla.  "Outcomes from the ORION trial support both the safety and efficacy of the Epic Stent and confirm its excellent performance in the treatment of atherosclerotic lesions in iliac arteries."

The prospective, single-arm ORION trial enrolled 125 patients at 28 sites in the United States. The trial met its primary endpoint, a composite rate of device- and/or procedure-related major adverse events (MAE) at nine months.  MAE are defined as death within 30 days, myocardial infarction (MI) occurring during hospitalization, target vessel revascularization (TVR) through nine months and amputation of the treated limb through nine months.  The Epic stent demonstrated a low MAE rate of 3.4 percent in the intent-to-treat population, significantly lower than the pre-specified performance goal of 17 percent (p<0.001) based on historical published outcomes for iliac stenting.  All reported major adverse events were related to TVR.  No deaths through 30 days and no amputations through nine months were observed.

Patients experienced significant clinical improvement from baseline based on feedback from validated questionnaires evaluating walking distance, speed and stair climbing. An additional measure of effectiveness based on the Rutherford Classification showed improvement in the patient population from 7.2 percent being asymptomatic or having mild claudication (class 0-1) at baseline to 82.3 percent of patients at 30 days and 81.6 percent at nine months.  Duplex ultrasound showed a primary patency of 95.9 percent, primary-assisted patency of 96.7 percent and secondary patency of 98.3 percent, indicating that treated lesions remained open through the nine-month follow-up period.

"We are pleased to report positive outcomes for U.S. patients in the ORION clinical trial.  The Epic stent has been used successfully in Europe for several years and we look forward to offering the device to U.S. physicians upon FDA approval," said Jeff Mirviss, president of Boston Scientific's peripheral interventions business.  

The Epic stent is a self-expanding nitinol stent designed to sustain vessel patency, while providing enhanced visibility and accuracy during placement.  It employs an innovative tandem architecture, which is engineered to provide improved stent flexibility while maintaining predictable radial force characteristics across the entire stent size matrix.  The Epic stent is compatible with 6F sheaths, and the stent delivery system is compatible with 0.035 inch guidewires. 

ORION clinical data is being used to support application for U.S. Food and Drug Administration (FDA) approval of the Epic Stent system, which was submitted in September 2011. 

The Epic nitinol stent system received CE Mark approval and was launched in Europe and other international markets in 2009.  In the United States it is an investigational device, limited to investigational use only and not available for sale.

For more information: www.bostonscientific.com